ASX ANNOUNCEMENT

FY25 Results - Investor Briefing Presentation

MELBOURNE, Australia (2 September 2025) – Lumos Diagnostics Holdings Ltd (ASX:LDX, "Lumos" or the "Company") a leader in rapid, point-of-care diagnostic technologies, is pleased to release a copy of the pr esentation to be delivered during a webinar for shareholders and investors to be held on Wednesday, 3 S eptember at 11:00am (AEST).

During the briefing, Chief Executive Officer, Doug Ward, Chief Financial Officer, Barrie Lambert, Senior VP Commercial Operations, Paul Kase, and VP Medical Affairs, Annie Bell will provide an overview of the results and general business update. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:

https://us02web.zoom.us/webinar/register/WN_0M3bwAatTXuiHquET0LMtQ

Once the registration form is completed, participants will receive a confirmation email with details on how to access the briefing.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598

Lumos Diagnostics Holdings Limited
FY25 Results Investor Briefing

3 September 2025

Financial information is shown in USD unless otherwise stated.

www.lumosdiagnostics.com

Disclaimer and Important Information

This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Non-IFRS financial measures

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, at the point-of-care.

Company Snapshot

Issued Capital	
Shares	753.5m
Options / Performance Rights	174.0m
Market Capitalization (AUD)	
Share price[1]	A$0.125
Market value	A$94.2m
Pro-forma Cash (30 June 2025 – in AUD)[2]	A$3.0m
Enterprise value	A$91.2m
Substantial Shareholders	
Tenmile Ventures	19.9%
Ryder Capital	17.0%

[1]As at close on 29 August 2025
[2]AUD:USD of 0.65

Share Price (AUD) & Volume



Board and Management

Sam Lanyon	Non-Executive Chair
Doug Ward	CEO & Managing Director
Bronwyn Le Grice	Non-Executive Director
Lawrence Mehren	Non-Executive Director
Catherine Robson	Non-Executive Director
Barrie Lambert	Chief Financial Officer

Key FY25 Highlights

Key Highlights From FY25 & Post Reporting Date

Revenue of US$12.4 million for the year, up 11% compared to prior year (FY24 - US$11.1 million). Adjusted EBITDA loss improved by 12% to US$3.4 million.

Major distribution agreement signed with PHASE Scientific for the U.S. market - for **US$317 million (A$487 million)** over 6 years,[1] assuming FebriDx® granted CLIA waiver and minimum order quantities (MOQ's) are achieved.

FebriDx - CLIA Waiver study completed, exceeding performance targets. Application submitted to FDA on 18 August 2025**.** Triggered US$2.8m in BARDA milestone and PHASE product prepayments. **Expected FDA feedback by end of Q1 CY2026**

FebriDx Pediatric study on children 2-12 years in a CLIA waived setting to commence with support from BARDA. Anticipated to run through the 2025/26 US respiratory season. Non-dilutive funding of US$6.2 million.

Hologic fFN project continues to progress, with Phase 2 work largely completed. Hologic requested additional studies on milestone 3, assay feasibility, which will delay Phase 3 by approx. 3-4 months.

Binding term sheet for A$5.0 million loan facility, with drawdowns as needed, to support working capital until after anticipated CLIA waiver grant for FebriDx.

[1]AUD:USD of 0.651 as at 15 July 2025

FY25 Financials

Profit & Loss Summary – FY25

Strong revenue growth and EBITDA improvement

(US$ in thousands)

Year ended 30 June	FY25	FY24	% Change
Services revenue	10,577	9,885	+7%
Products revenue	1,823	1,246	+46%
Total Revenue	**12,400**	**11,131**	**+11%**
Gross Profit	7,806	7,098	+10%
GP Margin (%)	*63.0%*	63.8%	*-0.8ppts*
Other income	1,518	138	n/m
Operating expenses	12,742	11,119	+15%
Adjusted EBITDA	**(3,418)**	**(3,883)**	**+12%**
Depreciation & amortisation	(2,528)	(2,649)	-5%
Finance Costs	(582)	(1,116)	-48%
Share based payments	(478)	(452)	+6%
Other	(177)	(492)	-64%
Income tax expense	-	-	-
Net (loss) after tax	**(7,183)**	**(8,592)**	**+16%**

Revenue

- Total revenue $12.4m (+11%)
- **Services revenue** $10.6m (+7%) - positive impact from Hologic Development and IP agreements, and other customer projects
- **Products revenue** $1.8m (+46%) - ViraDx sales in the US flu season and FebriDx US and International sales

Gross profit

- Gross profit $7.8m (+10%).
- GP margin 63.0% vs. 63.8%

Other income is primarily from BARDA grant of $1.2m recognised, and R&D tax rebate

Operating expenses

- $12.7m (+15%). Additional costs from FebriDx CLIA waiver trial, and some employee expenses (+4%)

EBITDA loss of $3.4m, an improvement of 12% from $3.9m in FY24

Balance Sheet Summary – FY25

Improved net current asset position

(US$ in thousands)

Period ending	30 Jun 2025	30 Jun 2024	+/-
Assets			
Cash	1,956	6,479	-4,523
Inventories	521	784	-263
Trade & other receivables	1,045	672	+373
Contract assets	2,324	1,010	+1,314
Right of use assets	5,984	7,267	-1,283
Intangibles	8,182	9,685	-1,503
Other assets	800	941	-141
Total Assets	**20,812**	**26,838**	**-6,026**
Liabilities			
Trade & other payables	2,919	2,389	+530
Lease liabilities	6,985	8,060	-1,075
Employee benefits	1,678	1,715	-37
Contract liabilities	3,073	7,565	-4,492
Total liabilities	**14,655**	**19,729**	**-5,074**
Net Assets	**6,157**	**7,109**	**-952**

- **Cash** as at 30 June was $2.0m
- **Inventory** mainly raw materials and finished goods for FebriDx. ViraDx inventory sold through
- **Trade & other receivables** includes BARDA receivable of $0.3m (received post balance date)
- **Contract assets** primarily accrued income (timing of accrual vs. milestone payments) on Hologic development agreement
- **Intangibles** consists of Lumos readers, FebriDx IP and other items (reduction due to amortization)
- **Contract liabilities** deposits and pre-payments by customers, mainly Hologic IP agreement
- **Net assets** includes capital raise during the 1H FY25

Cashflow Summary – FY25

Closing cash $2.0m - well supported capital raise

(US$ in thousands)

Year ended 30 Jun	FY25	FY24	+/-
Receipts from customers	6,368	16,536	-10,168
Payments to suppliers & employees	(16,334)	(15,524)	-810
Proceeds from grants	1,157	471	+686
Net interest received / (paid)	(525)	(537)	+12
Cash used in operating activities	**(9,334)**	**946**	**-10,280**
Payments for PP&E	(53)	(52)	-1
Capitalised product development	-	(46)	+46
Investing activities	**(53)**	**(98)**	**+45**
Proceeds from issue of shares (net of costs)	6,222	4,999	+1,223
Redemption of convertible notes	-	(1,110)	+1,110
Lease payments	(946)	(1,259)	+313
Financing activities	**5,276**	**2,630**	**+2,646**
Net decrease in cash	**(4,111)**	**3,478**	**-7,589**
Opening cash	6,479	3,015	+3,464
Effects of FX movement on cash	(412)	(14)	-398
Closing cash	**1,956**	**6,479**	**-4,523**

- **Receipts from customers** at $6.4m, is lower than revenue reported mainly due to recognising revenue on Hologic IP agreement (cash of $10m received in FY24) and accrued revenue on Hologic development agreement (monthly accrual vs. cash received on milestone achievement)
- **Payments to suppliers & employees** at $16.3m, increased by $0.8m, from FY24. Main movements are FebriDx CLIA waiver trial costs
- **Total cash burn** for FY25 is $10.3m vs. $0.4m in prior year (operating + investing + lease payments). Increase due to absence of Hologic IP payment of $10m, expenses on FebriDx CLIA waiver trial costs (where costs are refunded in arrears by BARDA) and working capital movements
- **Capital raise** in Sept/Oct 2024 - $6.2m (net of costs)
- **FX movement** on AUD held was negative $0.4m
- **Closing cash** as at 30 June 2025 of $2.0m (payments from BARDA $1.5m and PHASE Scientific $3.5m received post reporting date)

Binding term sheet for loan facility – Announced 17 July 2025

- Binding term sheet signed with supportive major shareholders Tenmile and Ryder Capital
- Funding of up to A$5.0 million, as required, on 12-month term, with option to extend by a further 12-months
- Subject to completing a definitive loan agreement and ASX waiver
- Anticipate a loan agreement to be executed by mid-September 2025
- In conjunction with cash receipts from PHASE Scientific distribution agreement and expected milestone payments from BARDA & Hologic, cash inflows should meet working capital requirements through to anticipated grant of CLIA waiver

The loan is designed to provide short term funding with limited equity dilution, while Lumos works toward a CLIA waiver for its flagship product, FebriDx®.

Products Division

About FebriDx®: Lumos' First-of-its-kind Point Of Care Test

FebriDx® is an aid for healthcare providers to improve patient care and antibiotic stewardship

- The majority of acute respiratory infections are caused by viruses and do not require antibiotics, yet antibiotics are prescribed in up to 50% of cases[1]
- Overprescription of antibiotics can result in adverse patient reactions and contribute to antimicrobial drug resistance
- FebriDx® is a rapid point-of-care test that uses a fingerstick blood sample to aid in the differentiation between bacterial and non-bacterial infections
- Rapid results at point of care can increase confidence in whether or not to prescribe an antibiotic.

1. Centers for Disease Control and Prevention (CDC). Measuring Outpatient Antibiotic Prescribing. Updated Oct 2022. Accessed Feb 2024, https://www.cdc.gov/antibiotic-use/data/outpatient-prescribing/index.html

FebriDx® A Simple And Unique Test For Microbial Infection

FebriDx® can rapidly identify patients who have a microbial infection[1] and, if positive, determine if that infection is caused by a viral or bacterial pathogen after 10 minutes

Key: Markers for infection

CRP	Inflammatory marker elevated with any infection
MxA	Specific marker only elevated with viral infection

FebriDx® Test Procedure and Interpretation of Results



BACTERIAL INFECTION

Patient can be treated with antibiotics

VIRAL INFECTION

VIRAL INFECTION

Viral Infection - Antibiotics will not work
Patient needs to be managed differently

1. Microbial infection is the invasion of infectious agents into the organism, their multiplication and the reaction of host tissue against these agents. Infectious agents include bacteria, virus, parasite and fungi.

FebriDx® Addresses A Major Need: Antibiotic Overprescription

ANTIBIOTICS PRESCRIBED (U.S.)

211M antibiotic prescriptions issued in outpatient settings each year [1]

44% of antibiotic prescriptions are written to treat patients with ARIs [2]

40% of these are unnecessary [3]

ANTIBIOTICS PRESCRIBED IN THE U.S. BY TYPE



Acute respiratory infections may account for

58%

of all antibiotics prescribed [4]

[1] Outpatient Antibiotic Prescriptions—United States 2021: https://www.cdc.gov/antibiotic-use/data/report-2021.html
[2] Unnecessary Antibiotics for Acute Respiratory Tract Infections: Associations with Care Setting and Patient Demographics, 2016
[3] Tse, J.; Near, A. *et al*; Antibiotics 2022, 11, 1058. https://doi.org/10.3390/ antibiotics11081.
[4] Centers for Disease Control and Prevention. MMWR, 2011, 60:1153-6

FebriDx® Journey To Transform The Practice Of Medicine

Recent achievements forming the critical commercialisation backbone for FebriDx®



PHASE Scientific Partnership

A pivotal agreement - one of the largest distribution deals of its type to be done by an ASX-listed point of care diagnostics company

Exclusive U.S. distribution agreement signed for FebriDx® with PHASE Scientific International

Partnership potential – for **US$317 million (A$487 million[1])** over 6 years,[2] assuming FebriDx® is granted CLIA waiver and minimum order quantities (MOQ's) are achieved

PHASE Scientific **MOQ's to ramp up significantly** from years 2 through to 6 of the agreement

Why PHASE?

- Expertise in POC market
- Highly regarded, well respected commercial leadership
- Financial commitment to a robust go-to-market launch
- Strong network of sub- distributors and end user customers.

Summary of anticipated payments (US$)

Milestones	Payment Timing	With CLIA waiver	Status
Exclusivity fee	On signing	1.0m	Received
Pre-paid purchase order	On signing	1.0m	Received
Pre-paid purchase order	On CLIA waiver application submission	1.5m	Received
Prep-paid purchase commitment	On grant of CLIA waiver	5.0m	
Aggregated minimum order quantities (Yrs 2-6)	On delivery of product	308.5m	
Total		**US$317.0m**	

1. AUD : USD = 0.651as at 15 July 2025 | 2. Subject to granting of CLIA waiver for FebriDx®. Without CLIA waiver contract size is estimated to be up to US$25.0 million.

FebriDx® CLIA Waiver Study Update

BARDA partnership agreement announced in October 2024

- BARDA partnership agreement: non-dilutive funding up to US$8.3 million committed to support CLIA waiver and pediatric studies (US$3.0m for CLIA waiver study and US$5.3m for pediatric study)

CLIA waiver clinical study commenced in December 2024

- The CLIA waiver study is designed to demonstrate that the FebriDx® test is simple to perform with a low risk of erroneous results when performed by untrained users in expanded user settings

CLIA waiver study application submitted 18 August 2025

- Study exceeded performance targets
- Demonstrated a 99.1% concordance between trained and untrained operators testing bacterial positive patients, and a 98.4% concordance for non-bacterial patients
- FDA CLIA waiver application submitted on 18 August 2025
- FDA feedback expected by end of Q1 CY2026
- The submission triggered $1.2 million in milestone payments from BARDA and $1.5 million FebriDx product prepayment milestone with Phase Scientific…now both received

FebriDx® US CLIA Waived Market Opportunity > US$1 Billion

A CLIA waiver allows facilities such as physician offices or urgent care centers to perform simple, low-risk tests without the full regulatory requirements of higher-complexity labs, provided they follow test instructions and maintain a CLIA Certificate of Waiver.

What is CLIA?

- **CLIA** stands for the **Clinical Laboratory Improvement Amendments** of 1988.
- It's a U.S. law that sets **quality standards** for all laboratory testing performed on humans (except for research only)
- Under CLIA, every lab (or facility performing tests) must be certified according to the **complexity of the tests** they perform:
  - **Waived** – Simple tests with low risk of errors
  - **Moderate Complexity** – More steps, training, and quality control needed
  - **High Complexity** – Requires skilled personnel, stringent oversight, and inspections.

MODERATE COMPLEXITY LIMITATION

CLIA WAIVER EXPANDS ADDRESSABLE MARKET



Moderate complexity settings ~7% (5.6 million patient interactions)

CLIA waiver enables 100% market coverage (80 million patient interactions)

Acute respiratory infections in U.S. annually: 80 million (potential FebriDx® patient opportunities for use)[1,2]

[1.] CMS, CLIA Database, 2024 (number of waived sites) and
[2.] Precision Business Insights, US Acute Respiratory Infections, 2024 (80 million annual acute respiratory consultations).

Lumos Partners with BARDA to Commence FebriDx® Pediatric Study

- FebriDx® is currently FDA-cleared for use in patients aged 12-64 years presenting to urgent care or emergency care settings for evaluation of acute respiratory infection
- Lumos to commence FebriDx® pediatric study in the US for use on children 2-12 years of age in a CLIA-waived settings
- Study launch anticipated in October 2025 to run through the 2025/26 US respiratory season
- The study will target the enrolment of around 500 patients, including 72 bacterial positive patients
- BARDA to support study through exercise of option (announced 1 September 2025) with expanded US$6.2 million non-dilutive funding package to accelerate the program
- Milestone payments from BARDA to Lumos to be triggered upon the achievement of each of twelve milestone events through to FDA 510(k)/CLIA waiver grant

"We look forward to working closely with BARDA once again to deliver this study and further expand the accessibility of FebriDx® to pediatric patients across the US"

Doug Ward
Lumos Diagnostics MD/CEO

The path to commercial adoption

Clinical Benefit

Only test that distinguishes between bacterial and non-bacterial acute respiratory infections at the point-of-care, enabling physicians to prescribe antibiotics appropriately and support antimicrobial stewardship.

Economic Benefit

Reimbursed under PLA code at $41.38 per test, creating sustainable margins for Lumos, distributors, and physicians while incentivizing adoption across the care network.

Operational Efficiency

Easily integrated alongside COVID/Flu combo tests without disrupting clinic workflow or patient throughput. Simple finger-prick test performed in under 10 minutes at triage.

Reimbursement 101: Path Of A New PLA Code



- 0442U: PLA Code assigned for FebriDx
- Provides a unique billing pathway and claims tracking

- CMS established rate on CLFS (Clinical Lab Fee Schedule) for FebriDx at US$41.38
- Serves as the initial reimbursement benchmark

- 6/7 MACs (Medicare Administrative Contractors) recognizing FebriDx at CLFS rate
- Pilot study rollout in moderate complexity CLIA certified sites (Urgent Care focus)
- Early in the process, denials are common and expected. Appeals help build precedent for coverage

- Pilot sites, as well as all current customers, bill for FebriDx and pursue denials/appeals while documenting outcomes
- Collect real world clinical and economic evidence

- Supports payer review and policy adoption for 0442U
- Evidence helps shift payors from case-by-case decisions toward policy-level adoption

- As CLIA waiver is granted and payor policies align, coverage expands, accompanied by market demand
- Reimbursement becomes more predictable with policy inclusions

Partnership with PRO-spectus provides a strategic pathway to coverage

Support pilot sites with denials and appeals to achieve positive case outcomes, while capturing real-world evidence that highlights market opportunities and uncovers reimbursement barriers.

The IVD Value Chain And Economic Flow

- **Manufacturers**
  - Role: R&D and production of IVD products
  - Gross Margin: ~60%
  - Margin Growth: Target 80% driven by volume, supplier price reduction, and manufacturing automation
- **Distributors**
  - Role: Sales to providers, logistics, warehousing, inventory management
  - Margins: Share of ~$41 (may be split with sub-distributors)
  - Revenue Drivers: Volume, efficiency, value-added services
- **Healthcare Providers / Physicians**
  - Role: Utilize tests for diagnosis and treatment monitoring
  - Revenue Drivers: Reimbursement for diagnostic services (not paid for prescribing antibiotics)
  - Impact: Improve patient management effectiveness and efficiencies as well as patient satisfaction
- **Payers**
  - Role: Determine coverage and reimbursement policies
  - Revenue Drivers: Premiums from beneficiaries
  - Influence: Shapes provider decisions through reimbursement rates

Lumos Future Products

Women's Sexual Health - $10B

Prevalence

Affects 30%-40% of women globally.
>10M heath care visits annually in the US



Clinical Need

Multiple infectious organisms.
Similar symptoms / hard to diagnose.
Different treatments for each. Patient samples currently sent to the core lab and can take days for results that potential mean delayed or incorrect diagnosis or treatment



POC Diagnostic Opportunity

Rapid & accurate testing close to the patient is needed. With a POC test(s), physicians can identify & treat at first patient visit. Easy to use & trusted by clinic staff

Women's Sexual Health – The Opportunity

IN CLINIC TESTING

Physical Exam



Microscopic Exam

Pathogen Testing

EXTERNAL LAB TESTING

Pathogen Testing

Current Practice









Lumos Women's Sexual Health POC tests will be run by existing staff, cost effective and provide rapid and accurate results

Reimbursement codes are available today

Majority of clinics do not have in house testing of sexual health pathogens, due to test complexity, overheads and cost

Instead, clinics send out testing to external labs, delaying patient diagnosis and treatment

Lumos Product Roadmap | Women's Sexual Health

CURRENT - DISTRIBUTION
Revenue & Market Learning

FUTURE - LUMOS POC PRODUCTS
Pathogen Detection | Visual & Reader Interpretation

GYN CLINIC & URGENT CARE

Lumos – As a Distributer

Lumos Products – Visual Read

Lumos Products on Lumos Reader

Binx io
Chlamydia & Gonorrhea

Product #3

Product #4

Product #5

Product #1

Product #2

Concept Development

Technical Feasibility

Product Development

Verification & Validation

Commercialization

LUMOS DIAGNOSTICS

Commercial Services Division

Commercial Services Capabilities

Lumos offers the full range of in-house expertise required to deliver a complete, commercially ready solution

DEVELOPMENT & MANUFACTURING

PLATFORM TECHNOLOGIES

ASSAY

READERS

EMR & CONNECTIVITIY

Hologic - Strategic Partnership

Fetal Fibronectin (fFN)[1]

Historic relationship with Lumos <> Hologic – working together at multiple levels

Two agreements signed in FY24 for the development of an improved version of one of Hologic's leading in-market women's health products, **Fetal Fibronectin (fFN)**, including adapting it for use on Lumos' proprietary reader platform.

- **IP Agreement** - US$10.0m - exclusive license to the Lumos proprietary reader and POC technologies for next generation fFN product – **received in FY24**
- **Development Agreement** - up to US$6.4m over an estimated 27-month period for the following milestones:
  - **Phase 1: Product Definition and Planning** - US$0.4m - **completed**
  - **Phase 2: Assay Feasibility** - US$0.6m – milestone 1 **completed** / milestone 2 **completed** / milestone 3 **largely completed** Additional assay studies requested by Hologic, estimated to take 3-4 months and extra US$0.9m in fees
  - **Phase 3: System Prototype Delivery** – US$3.7m – milestones 4 to 9 – **commenced** milestones 4 & 5, now delayed pending additional assay studies
  - **Expanded hardware scope of work** – announced Mar 2025 - US$0.8m for delivery of new hardware features - **commenced**
- **Expected Development Agreement completion around August 2026** (extended from March 2026 due to additional assay studies)

[1]ASX announcements 11 January 2024, 15 January 2024, 16 January 2024, 6 May 2024, 4 June 2024, 19 June 2024. 3 March 2025 2. Global Market Insights, www.gminsights.com

fFN is a biomarker indicating a heightened risk of pre-term delivery and is the largest segment of the pre-term birth diagnostic kit market



Hologic - fFN Product Development Overview And Opportunity

Current test: Rapid fFN TLiQ

Next generation test concept (mock-up)

Hologic – the opportunity ahead

- Verification and validation
- Clinical study
- Manufacturing
- Second test development and IP

Aptatek Phenylketonuria (PKU) In-home Monitoring Device

- PKU affects 1 in 12,000 newborns, leading to neurological complications if un-checked
- Lumos secures follow-on contract to move PKU in-home monitoring device to next stage of clinical development and commercial readiness
- $1.5 million contract commencing September, to be charged on time-and-materials basis
- Lumos to focus on:
  - Maturing the design of the tests
  - Blood processing unit and readers
  - Formal verification testing to ensure the device meets product requirements for clinical trials and FDA submission

Key Priorities

FDA decision on the CLIA waiver for FebriDx® is expected between November 2025 and February 2026.

Implement agreement with PHASE Scientific, advance national payer coverage through our partnership with Pro-spectus, and plan for volume scale-up.

Initiate FebriDx pediatric study in October – fully funded by BARDA - addresses important clinical market and expands U.S. market by approx. 20%

Deliver on Hologic fFN development milestones - additional milestone 3 studies from Phase 2 & Phase 3 milestones 4 -9

Progress to formal product development on the first Lumos branded women's health diagnostics test

LUMOS
DIAGNOSTICS

www.lumosdiagnostics.com